Clofarabine. Bioenvision/ILEX.
Author(s): Sternberg A
Affiliation(s): Academic Department of Haematology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, UK. stern@molbiol.ox.ac.uk
Publication date & source: 2003-12, Curr Opin Investig Drugs., 4(12):1479-87.
Publication type: Review
Clofarabine is a purine nucleoside antimetabolite under development by Bioenvision (under license from the Southern Research Institute) and ILEX for the potential treatment of solid tumors, acute myelogenous leukemia, non-Hodgkin's lymphoma, and acute lymphoblastic and chronic lymphocytic leukemia. In September 2003, Bioenvision initiated a phase II trial in Europe in pediatric acute lymphoblastic leukemia, and in October 2003, ILEX submitted the first part of a rolling NDA to the FDA for the treatment of acute leukemia in children.
|